Domainex's newsletter brings you up to speed on the latest announcements from the team.
No images? Click here
Domainex newsletter
All the latest news and industry insights from the Domainex team
We are proud to have featured in the very first edition of the Financial Times ‘Europe’s Long-Term Growth Champions’ special report compiled in partnership with Statista. This study aimed to identify and highlight European enterprises with long-term sustained organic growth and included companies from over 30 countries, across all sectors. The list builds on the established FT 1000 concept.
Nuclera’s eProtein Discovery system installed at Domainex to streamline protein production services
Domainex is the first contract research organisation (CRO) to have installed the eProtein Discovery system and offer protein production services using the technology.
Drug discovery webinar series off to a great start
Domainex has launched a new webinar series sharing our expertise on some of the latest advancements in drug discovery research. The series is hosted by One Nucleus and features informative sessions run by experts from across Domainex. Don't worry if you missed any of the webinars, you can catch up online now.
The reemergence of covalent compounds: Domainex’s approach to covalent fragment screening
Our next webinar will be at 2pm on Monday 9th December. Andrew Ratcliffe, Head of Chemistry, and Scott Martin, Head of the Bioanalytical Sciences Department, will discuss our approach to identifying high quality covalent fragment hits. Register now!
RuvBL1/2: Cryo-EM analysis of a hetero-hexameric AAA+ ATPase
RuvBL1/2 has been shown to play a key role in assembly and maturation of large molecular PIKK family complexes and as such is important in the development of novel cancer therapeutics. Domainex has applied Cryo-EM to generate a high-resolution structure of the nucleotide-binding site of RuvBL1/2.
Adenosine A2a receptor: Novel Biophysical Fragment Screening using Polymer-Encapsulated Nanodiscs
For the first time, Domainex has demonstrated that polymer nanodics can be used in conjunction with Spectral Shift for fragment screening – expanding the targets that fragment screening can be used for and opening up the potential to develop novel therapeutic agents. This is demonstrated via the Adenosine A2a receptor.
Direct-to-biology (D2B) beyond amide couplings
Domainex has developed a novel D2B protocol, building on our previously developed D2B protocol that uses amide coupling chemistry. We have now validated a novel azidation/CuAAC two-step one-pot protocol, offering a complementary pathway to access distinct chemical space for rapid biological screening.
High-Throughput Experimentation (HTE) Approaches at Domainex: The Advantages of “End-User Plates”
High-throughput experimentation (HTE) has become a core foundation of modern organic chemistry reaction optimisation. The Domainex team has developed “end-user plates”; pre-prepared glass vials containing the requisite catalyst stored under inert or refrigerated conditions, in order to further optimise the process.
New recruits
Welcome to Gareth Davies (Principal Scientist, Assay Biology) and Chris Miller (Business Development Director) who have recently joined the Domainex team.
New publications
Upcoming events
Genesis 2024
4th December | London, UK
Recent Trends in Medicinal Chemistry and Enabling Technologies
5th December | London, UK
Webinar | The reemergence of covalent compounds: Domainex’s approach to covalent fragment screening
9th December | Online
